43 related articles for article (PubMed ID: 10929004)
1. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
[TBL] [Abstract][Full Text] [Related]
3. Keyhole limpet hemocyanin contains Gal(beta 1-3)-GalNAc determinants that are cross-reactive with the T antigen.
Wirguin I; Suturkova-Milosević L; Briani C; Latov N
Cancer Immunol Immunother; 1995 May; 40(5):307-10. PubMed ID: 7600562
[TBL] [Abstract][Full Text] [Related]
4. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate.
Kleski KA; Trabbic KR; Shi M; Bourgault JP; Andreana PR
Molecules; 2020 Mar; 25(6):. PubMed ID: 32183149
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.
Pan Y; Chefalo P; Nagy N; Harding C; Guo Z
J Med Chem; 2005 Feb; 48(3):875-83. PubMed ID: 15689172
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of the Thomsen-Friedenreich-antigen (TF-antigen) and binding of Galectin-3 to TF-antigen presenting neo-glycoproteins.
Hoffmann M; Hayes MR; Pietruszka J; Elling L
Glycoconj J; 2020 Aug; 37(4):457-470. PubMed ID: 32367478
[TBL] [Abstract][Full Text] [Related]
9. Valency and density matter: Deciphering impacts of immunogen structures on immune responses against a tumor associated carbohydrate antigen using synthetic glycopolymers.
Qin Q; Yin Z; Wu X; Haas KM; Huang X
Biomaterials; 2016 Sep; 101():189-98. PubMed ID: 27294537
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles.
Biswas S; Medina SH; Barchi JJ
Carbohydr Res; 2015 Mar; 405():93-101. PubMed ID: 25556664
[TBL] [Abstract][Full Text] [Related]
11. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer.
Wang CC; Huang YL; Ren CT; Lin CW; Hung JT; Yu JC; Yu AL; Wu CY; Wong CH
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11661-6. PubMed ID: 18689688
[TBL] [Abstract][Full Text] [Related]
12. Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6.
Ulsemer P; Henderson G; Toutounian K; Löffler A; Schmidt J; Karsten U; Blaut M; Goletz S
Cancer Immunol Immunother; 2013 May; 62(5):875-87. PubMed ID: 23381581
[TBL] [Abstract][Full Text] [Related]
13. Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.
Irazoqui FJ; Lopez PH; Vides MA; Nores GA
Glycobiology; 2000 Aug; 10(8):781-7. PubMed ID: 10929004
[TBL] [Abstract][Full Text] [Related]
14. Influence of terminal residue on adjacent disaccharide immunogenicity.
Irazoqui FJ; Lopez PH; Mandel U; Nores GA
Mol Immunol; 2002 Mar; 38(11):825-31. PubMed ID: 11922940
[TBL] [Abstract][Full Text] [Related]
15. Correlative fine specificity of several Thomsen-Friedenreich disaccharide-binding proteins with an effect on tumor cell proliferation.
Irazoqui FJ; Jansson B; Lopez PH; Nores GA
J Biochem; 2001 Jul; 130(1):33-7. PubMed ID: 11432777
[TBL] [Abstract][Full Text] [Related]
16. Immune response to Thomsen-Friedenreich disaccharide and glycan engineering.
Irazoqui FJ; Sendra VG; Lardone RD; Nores GA
Immunol Cell Biol; 2005 Aug; 83(4):405-12. PubMed ID: 16033536
[TBL] [Abstract][Full Text] [Related]
17. Thomsen-friedenreich disaccharide immunogenicity.
Irazoqui FJ; Nores GA
Curr Cancer Drug Targets; 2003 Dec; 3(6):433-43. PubMed ID: 14683501
[TBL] [Abstract][Full Text] [Related]
18. Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy.
Almogren A; Abdullah J; Ghapure K; Ferguson K; Glinsky VV; Rittenhouse-Olson K
Front Biosci (Schol Ed); 2012 Jan; 4(3):840-63. PubMed ID: 22202095
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
